ENTX
Entera Bio Ltd.
There isn't enough reported data to score ENTX yet.
ENTX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
ENTX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
ENTX PE Valuation
ENTX has no meaningful PE right now: it lost money over the past year.
ENTX Forward outlook
There aren't enough analyst estimates for ENTX to show an outlook.
ENTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.38 | -$0.13 |
| Q2 2026 | -$0.34 | -$0.08 |
| Q1 2026 | -$0.26 | $0.00 |
| Q4 2025 | -$0.25 | $0.00 |
| Q3 2025 | -$0.25 | +$0.01 |
| Q2 2025 | -$0.26 | $0.00 |
| Q1 2025 | -$0.26 | +$0.02 |
| Q4 2024 | -$0.25 | +$0.06 |
ENTX is still losing money, but far less than before: $0.38 per share over the past year, against $0.92 at its worst in late 2019.
ENTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $14K | -92% |
| Q3 2022 | $8K | -94% |
| Q2 2022 | $44K | -60% |
| Q1 2022 | $68K | -57% |
| Q4 2021 | $165K | -25% |
| Q3 2021 | $140K | +180% |
| Q2 2021 | $109K | +110% |
| Q1 2021 | $157K | +274% |
ENTX's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -6102% | N/A |
| Q4 2024 | -2850% | N/A |
| Q3 2024 | -7193% | N/A |
| Q2 2024 | -3798% | N/A |
| Q4 2022 | -21914% | -19413 points |
| Q3 2022 | -35813% | -38113 points |
| Q2 2022 | -7384% | -5026 points |
| Q1 2022 | -5640% | -4150 points |
ENTX's operating margin was −6102% last quarter, up 15812 points from the same quarter a year ago.
ENTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.4M | -$4.9M |
| Q2 2026 | -$3.5M | -$1.8M |
| Q1 2026 | -$3.1M | -$1.7M |
| Q4 2025 | -$1.9M | -$390K |
| Q3 2025 | -$2.5M | -$391K |
| Q2 2025 | -$1.7M | -$325K |
| Q1 2025 | -$1.4M | +$450K |
| Q4 2024 | -$1.5M | +$1.2M |
ENTX has burned cash in almost every quarter: −$16M over the past year, against −$7M the year before.
ENTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +188% | +94.6M shares |
| 1 year | +208% | +98M shares |
| 3 years | +403% | +116M shares |
| 5 years | +487% | +120M shares |
| Available history | +1104% | +133M shares |
ENTX has 145M diluted shares, up 208% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ENTX Net Leverage
ENTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ENTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.7 | Neutral |
| Stochastic | 58.6 | Neutral |
ENTX's weekly RSI is 67 (neutral) and its Stochastic is 59 (neutral).
ENTX PE vs Healthcare Sector
ENTX has no meaningful PE right now: it lost money over the past year.
ENTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.93 | 9.9% above |
| 20 week MA | $2.73 | 18% above |
| 50 week MA | $1.94 | 66% above |
| 100 week MA | $2.03 | 59% above |
| 200 week MA | $1.65 | 95% above |
ENTX is in an uptrend: it's above all five of its weekly moving averages, and 95% above its 200-week average.
ENTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.01 | $1.07 | -47% |
| 2021 | $1.07 | $3.05 | +185% |
| 2022 | $3.05 | $0.55 | -82% |
| 2023 | $0.55 | $0.60 | +9.1% |
| 2024 | $0.60 | $2.15 | +258% |
| 2025 | $2.15 | $1.72 | -20% |
| 2026 YTD | $1.72 | $3.22 | +87% |
ENTX's yearly returns have swung widely, from +258% in 2024 to −82% in 2022. It's up 87% so far in 2026.